Who invested in CND Life Sciences

2 rounds we have observed, with the one investor named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Raised 3 months ago

Funding summaryUpdated 26 Oct 2026

$17Mraised across 2 rounds since 2025, from 2 sources

$3.0MGrant$14MGrowth

Latest round: Growth, $14MAug 2026
Step-upi: 4.5×
Investors: 1

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

2026

$3.0MGrant$14MGrowth

First round: Grant, $3.0M
Biggest round: $14M
Between rounds: 10 months

The rounds

Aug 2026
Growth$14M1 returning
- National Institutes of Health
Source recordedSEC filing: $6.3M sold, first sale Jun 2026
Oct 2025
Grant$3.0M1 new
- National Institutes of Health
Source recorded

Founders and team

From CND Life Sciences's own website: 20 on the team.

Richard J. MorelloChief Executive Officer
Sowmya ArunkumarSenior Vice President, Regulatory Affairs and Quality Assurance
Hernan LopezChief Operating Officer
Bryan MayVP, Information Technology
Alex RadivoyevichDirector of IT
Bailey BellaireDirector, Digital Pathology Operations & Process Engineering
Brandy MaschhauptDirector, Clinical Study Operations
Jack SeaverBoard Director
Jade StohlClinical Program Manager
Janine FengSenior Pathology Consultant
Jeannie FarnsworthSenior Director, Clinical Research and Biomarker Services
Jennifer WhitneyDirector, Brand Marketing
Jimmie EvansLaboratory Director
Karina SolisDirector, Billing Services & Operations
Kathryn Van WieGeneral Counsel & SVP, Growth & Market Access
Mackenzie TroutmanDirector, Clinical Services
Peter HarrisBoard Chair
Steve MastrianDirector, Research Operations

And 2 more on the team.

Everyone who backed them

National Institutes of HealthGovernment2rounds

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 2 firms list CND Life Sciences as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.